American Century Companies Inc. Sells 762,886 Shares of Halozyme Therapeutics, Inc. $HALO

American Century Companies Inc. trimmed its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 85.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 132,526 shares of the biopharmaceutical company’s stock after selling 762,886 shares during the period. American Century Companies Inc. owned 0.11% of Halozyme Therapeutics worth $6,894,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in HALO. Redhawk Wealth Advisors Inc. increased its stake in shares of Halozyme Therapeutics by 14.8% in the 2nd quarter. Redhawk Wealth Advisors Inc. now owns 37,419 shares of the biopharmaceutical company’s stock worth $1,947,000 after acquiring an additional 4,827 shares in the last quarter. Intech Investment Management LLC grew its holdings in Halozyme Therapeutics by 9.9% in the first quarter. Intech Investment Management LLC now owns 153,199 shares of the biopharmaceutical company’s stock worth $9,776,000 after purchasing an additional 13,789 shares during the period. Focus Partners Wealth grew its holdings in Halozyme Therapeutics by 57.8% in the first quarter. Focus Partners Wealth now owns 120,815 shares of the biopharmaceutical company’s stock worth $7,709,000 after purchasing an additional 44,260 shares during the period. Livforsakringsbolaget Skandia Omsesidigt increased its stake in shares of Halozyme Therapeutics by 78.0% during the second quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 102,000 shares of the biopharmaceutical company’s stock valued at $5,305,000 after purchasing an additional 44,700 shares in the last quarter. Finally, Shelton Wealth Management LLC purchased a new position in shares of Halozyme Therapeutics during the second quarter valued at approximately $843,000. Hedge funds and other institutional investors own 97.79% of the company’s stock.

Halozyme Therapeutics Stock Up 0.6%

Shares of Halozyme Therapeutics stock opened at $63.33 on Friday. Halozyme Therapeutics, Inc. has a twelve month low of $46.26 and a twelve month high of $79.50. The company has a quick ratio of 1.37, a current ratio of 1.59 and a debt-to-equity ratio of 1.59. The company’s 50 day moving average is $68.18 and its 200 day moving average is $64.34. The company has a market cap of $7.45 billion, a price-to-earnings ratio of 13.33, a price-to-earnings-growth ratio of 0.34 and a beta of 0.95.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Monday, November 3rd. The biopharmaceutical company reported $1.72 earnings per share for the quarter, beating analysts’ consensus estimates of $1.63 by $0.09. The business had revenue of $354.26 million during the quarter, compared to analyst estimates of $339.18 million. Halozyme Therapeutics had a net margin of 47.91% and a return on equity of 156.95%. The company’s quarterly revenue was up 22.1% compared to the same quarter last year. During the same period in the previous year, the business earned $1.27 EPS. Research analysts anticipate that Halozyme Therapeutics, Inc. will post 4.73 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently weighed in on HALO. Citigroup reaffirmed a “market outperform” rating on shares of Halozyme Therapeutics in a research report on Tuesday, November 4th. HC Wainwright restated a “buy” rating and set a $90.00 price target on shares of Halozyme Therapeutics in a report on Friday, November 28th. Weiss Ratings reiterated a “buy (b-)” rating on shares of Halozyme Therapeutics in a research note on Monday, December 1st. Leerink Partners upgraded shares of Halozyme Therapeutics from an “underperform” rating to a “market perform” rating and set a $70.00 price objective for the company in a research note on Tuesday, October 14th. Finally, Citizens Jmp upped their target price on shares of Halozyme Therapeutics from $91.00 to $92.00 and gave the stock a “market outperform” rating in a research note on Tuesday, November 4th. Seven analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Halozyme Therapeutics has an average rating of “Hold” and an average price target of $75.10.

Insider Buying and Selling

In related news, CEO Helen Torley sold 16,569 shares of the company’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $68.92, for a total transaction of $1,141,935.48. Following the completion of the sale, the chief executive officer owned 708,719 shares in the company, valued at approximately $48,844,913.48. This represents a 2.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Bernadette Connaughton sold 829 shares of the stock in a transaction dated Monday, December 1st. The shares were sold at an average price of $71.60, for a total value of $59,356.40. Following the completion of the transaction, the director directly owned 42,123 shares in the company, valued at approximately $3,016,006.80. This represents a 1.93% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 103,625 shares of company stock valued at $7,446,727 over the last 90 days. Company insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.